News

Two key health provisions in the House “BBB “ would empower CMS to negotiate the prices of 10 drugs starting in 2023 and put a limit of $2,000 on Medicare Part D annual out-of-pocket costs.

U.S. workers plan to spend more time reviewing their healthcare options and enrolling in new benefits during this enrollment period

Pfizer/BioNTech plan to use this data to support submissions for full approval of the vaccine in those 12 to 15 years old.

Momentum is building for biosimialrs but robust coverage for lower-cost agents, including biosimilars, is needed.

As industries across the board move towards a digital-only world, pharma companies must account for the different technologies that are transforming the R&D process.

In COVID-19 news, FDA expands EUA for Moderna/Pfizer boosters and Pfizer seeks EUA for oral antiviral. Keytruda receives another indication, first therapy is approved for dwarfism, FDA extends review of mavacamten, and Gilead submits application for chronic hepatitis therapy.

The decision on the fate of the novel therapy for hypertrophic cardiomyopathy was delayed because the agency said it needed more time to consider the risk evaluation and mitigation strategy (REMS) for the drug.

Using predictive analytics to address social determinants of Health and transportation barriers.

JAMA Internal Medicine editor and a UCSF colleague wrote in a New England Journ of Medicine opinion piece that the decision highlights the need to establish a new requirement that would make coverage decisions contingent on evidence of benefit for Medicare population.

In this week’s episode Briana Contreras, associate editor of Managed Healthcare Executive, met with Greg Miller, vice president of Industry Strategy, Healthcare and Life Sciences at Talkdesk. The two discussed that while virtual care has become a convenient tool in healthcare during the pandemic and has helped treat more patients, this form of care isn’t completely solving patient’s underlying issues. However, Miller shared how AI is helping ease the patient experience and improving care in this conversation.

ICER’s review indicates that Humira’s price increases are not supported by new clinical evidence.

Despite advances in medical science and technology, our healthcare system doesn’t always translate knowledge into practice. All too often, this leaves healthcare providers questioning the key business decisions that impact patient care. What caregivers need is a model for applying new technology safely and appropriately. Thankfully, such a model exists: the High Reliability Organization (HRO) model.

A new study suggests clinicians might be able to use metabolic “fingerprints” to better understand the likely severity of individual cases.

Collaboration among stakeholders is needed to increase transparency of pharmacy payment programs and to better align the design of these models with good patient care.

Branded and unbranded versions of the interchangeable biosimilar to treat patients with diabetes are now available.

Investigators in Japan have developed a new, noninvasive method for screening for spinal muscular atrophy using saliva analyzed with conventional PCR as an alternative to blood-based genetic screening.

The integration of virtual and in-person care, and expansion of mental health services is among the top health and well-being trends for next year.

Long term care industry facing worst job loss among all healthcare providers.

President Biden nominates new FDA commissioner, and the agency has approved a liquid form of a seizure medication and a new treatment for a rare blood disease. The FDA also accepted a supplemental NDA for Jardiance this week.

For health insurance executives, pursuing the Quadruple Aim is the name of the game.

Califf, who is described by some as a safe choice for the agency’s top job, headed the FDA during the last year of the Obama administration.

Site of service has a major effect on the cost. Home infusion and oral formulations are challenging both hospital- and physician-based infusions.

Patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, and multiple myeloma were more likely to have a COVID-19 breakthrough infection.

Smaller PBMs are rated higher by health plans in terms of satisfaction because of their ability to offer more customized solutions.

In an interview with Managed Healthcare Executive®, Ty Gluckman, M.D., FACC, FAHA, provides helpful explanations of hypertrophic cardiomyopathy diagnosis and treatment

Treating high levels of low-density lipoprotein cholesterol in young people may reduce lifetime exposure and lead to fewer cases of coronary heart disease.

A new report suggests infants who do not get enough sleep can quickly become overweight.